ADARx Pharmaceuticals

Founder-CEO Zhen Li has deep siRNA credentials from Arrowhead and Merck, the team includes an experienced CMO and CFO, and founder ownership is meaningful post‑offering, which aligns incentives. Governance appears standard for a newly public biotech.

Execution track record includes advancing three clinical programs, landing a major AbbVie partnership, and financing through an upsized IPO. The next test is clinical and regulatory execution through 2027.